DISC Department of Integrated Surgical and Diagnostic Science, School of Medical and Pharmaceutical Sciences, University of Genoa, Genoa, Italy.
DiMI Department of Internal Medicine Osteoporosis, Bone and Joint Disease Research Center, CROPO, Genoa, Italy.
Curr Rheumatol Rev. 2022;18(1):2-11. doi: 10.2174/1573397117666211006094117.
Osteoarthritis (OA) is a chronic disease characterized by inflammation and progressive deterioration of the joint. The etiology of OA includes genetic, phlogistic, dismetabolic and mechanical factors. Historically, cartilage was considered the target of the disease and therapy was aimed at protecting and lubricating the articular cartilage. The osteochondral unit is composed of articular cartilage, calcified cartilage, and subchondral and trabecular bone, which work synergistically to support the functional loading of the joint. Numerous studies today show that OA involves the osteochondral unit, with the participation therefore of the bone in the starting and progression of the disease, which is associated with chondropathy. Cytokines involved in the process leading to cartilage damage are also mediators of subchondral bone edema. Therefore, OA therapy must be based on the use of painkillers and bisphosphonates for both the control of osteometabolic damage and its analgesic activity. Monitoring of the disease of the osteochondral unit must be extensive, since bone marrow edema can be considered as a marker of the evolution of OA. In the present review, we discuss some of the pathogenetic mechanisms associated with osteoarthritis, with a particular focus on the osteochondral unit and the use of clodronate.
骨关节炎(OA)是一种以炎症和关节进行性恶化为特征的慢性疾病。OA 的病因包括遗传、炎症、代谢紊乱和机械因素。从历史上看,软骨被认为是疾病的靶点,治疗旨在保护和润滑关节软骨。软骨下骨单元由关节软骨、钙化软骨和软骨下骨及小梁骨组成,它们协同工作以支撑关节的功能负荷。如今,许多研究表明 OA 涉及软骨下骨单元,因此骨骼参与了疾病的起始和进展,这与软骨病有关。参与导致软骨损伤过程的细胞因子也是软骨下骨水肿的介质。因此,OA 治疗必须基于使用止痛药和双膦酸盐,以控制骨代谢损伤及其镇痛活性。必须广泛监测软骨下骨单元的疾病,因为骨髓水肿可被视为 OA 演变的标志物。在本综述中,我们讨论了一些与骨关节炎相关的发病机制,特别关注软骨下骨单元和氯膦酸盐的使用。